This market resolves YES iff the human brain preservation company Nectome (https://nectome.com/) still exists and is taking new patients at the start of 2032.

If Nectome still technically exists, but is not able to preserve new patients (perhaps because they are not legally able to do so, or are purely devoted at that point to protecting the patients they've already preserved). If Nectome clearly falls apart, I'll resolve NO early, but I will err on the side of waiting to resolve if things are dicey. If a company offering human preservation via aldehyde fixation that is clearly descended from Nectome in terms of staff/technology AND that company accepts Nectome prepurchases made in 2026, this can resolve YES even if that company is not named Nectome and/or is technically a distinct legal entity.